The FDA said its investigation shows that only the two recalled lots were potentially contaminated, and no adverse event reports have been received.
The agency said that administering dexmedetomidine with trace amounts of lidocaine to a patient could cause anaphylaxis, which can be life-threatening.
Read the FDA’s full news release here.
More articles on pharmacy:
NIH updates remdesivir treatment guidelines
J&J to start human trials for COVID-19 vaccine this week
Growing number of polls find Americans hesitant about getting a future COVID-19 vaccine
